Originally published by Fierce Biotech.
Prefilled syringes (PFSs) are emerging as a preferred presentation for new injectable biologic medications. Compared with single and multidose vials, PFSs are ideal for subcutaneously (SQ) administered injectables because they reduce the number of steps needed to prepare the dose, and SQ delivery is generally less painful than intravenous (IV) administration. Therefore, administration using a PFS offers real advantages to both healthcare professionals and patients, especially when treating chronic diseases. However, there are barriers to switching to PFS and SQ delivery that complicate efforts to realize those benefits. This article describes the benefits of transitioning from IV to SQ administration, considers the advantages of using PFSs, and explores challenges and solutions for transitioning from vials to PFS.